Evaluation of Acute Rejection Rates in de Novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (Belatacept)-Based Immunosuppression

The purpose of this study is to assess the incidence of acute rejection by 6 months in de novo renal transplant recipients treated with Belatacept following induction therapy with Thymoglobulin, and used in conjunction with adjunct immunosuppression with Mycophenolate Mofetil (MMF) or Everolimus and corticosteroids.